Compare Incyte Corporation (INCY) vs Janus Living Inc. Class A-1 Common Stock (JAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Janus Living Inc. Class A-1 Common Stock — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.63B), while Janus Living Inc. Class A-1 Common Stock trades at $28.51 (market cap $6.79B). The key difference: Incyte Corporation is far larger — about 3.3× Janus Living Inc. Class A-1 Common Stock's market cap, and Janus Living Inc. Class A-1 Common Stock pays a 1.97% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Janus Living Inc. Class A-1 Common Stock for 0 Days on average.
| INCY | JAN | |
|---|---|---|
Market Cap | $22.63B | $6.79B |
Volume | 1,869,988 | 1,802,875 |
Sector | Health | Real Estate |
52-Week High | $129.93 | $31.76 |
52-Week Low | $86.17 | $22.88 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $18.13B | $6.88B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $108.62, down 2.46% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 13.84, robust profitability margins, and a significant earnings beat in Q2 2026. Recent news highlights FDA approval for Atebrioz and a strategic push for post-JAKAFI growth targeting $4B in sales. Operating cash flow surged to $1.41B in 2025, supporting financial health.
The outlook is mixed: analyst consensus is bullish with a $133.14 price target, but near-term technical pressure and Q3 2026's expected EPS loss pose risks. Long-term growth depends on pipeline execution and diversification beyond JAKAFI, with competitive and regulatory challenges as key investor considerations.
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Janus Living Inc. Class A-1 Common Stock
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →
